PHILADELPHIA--(BUSINESS WIRE)--Nov. 18, 2005--ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today that preclinical data for ZIO-102, an organic arsenic derivative, was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, PA. The abstract titled "Mechanisms of increased reactive oxygen species (ROS) generation induced by organic arsenic derivative dipropil-s-glycerol arsenic (ZIO-102)" was presented in a poster presentation. Xiaodong Cheng, of the University of Texas M.D. Anderson Cancer Center and coworkers conducted the study.
